课题基金 / 基金详情

GENETIC MANIPULATION OF TUMOR RADIORESISTANCE

GENETIC MANIPULATION OF TUMOR RADIORESISTANCE
肿瘤放射抗性的基因调控
批准号:
6475011
负责人:
KRISTOFFER Carl VALERIE
金额:
$18.41万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-08-01 至 2003-07-31

项目摘要

项目成果

KRISTOFFER Carl VALERIE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: (Applicant's Description) Certain drugs act synergistically with radiation to increase cell killing. However, the specific sensitization of tumor cells to radiation over that of normal cells has been a limiting factor where one can potentially make major advances is to radio-sensitize tumor cells through genetic manipulation (transient gene therapy) with highly infectious recombinant adenoviruses. The basic concept is to introduce a gene into tumor normal cellular proteins to allow for tumor-specific chemical radio-sensitization. In this proposal we will specifically radio-sensitize p53 wild-type and mutant rat glioma cells in vitro and in vivo and human glioma cells in vitro by delivering the Herpes simplex Virus (HSV) thymidine kinase (TK) gene with the nucleosides which are specifically infectious adenovirus and exposing the cells to modified nucleosides which are specifically phosphorylated by HSV-TK and incorporated into tumor cell DNA. Incorporation of the halogenated pyrimidines bromodeoxycytidine and iododeoxycytidine, and the DNA chain-terminator acyclovir is expected to radio-sensitize the cells. The p53 suppressor gene is likely to influence this radio-sensitivity and in close collaboration with Project 4, we will investigate the role of p53 in HSV-TK-mediated radio-sensitization of gliomas. Because a direct correlation exists between cell proliferation, DNA incorporation of modified nucleosides, and extent of radio- sensitization, attempts will also be made to stimulate cell proliferation by genetically manipulating the expression of thioredoxin, a growth factor and transcriptional activator associated with ribonucleotide reductase which is intimately linked to nucleoside biosynthesis and DNA synthesis. Results from these studies will increase our understanding of how to efficiently delivery recombinant adenovirus in situ with the purpose of chemically radio-sensitize gliomas.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Glioblastoma radioimmunotherapy
  • 批准号:
    10057915
  • 项目类别:
  • 资助金额:
    $23.29万
  • 财政年份:
    2020
  • 负责人:
    KRISTOFFER Carl VALERIE
  • 依托单位:
Glioblastoma radioimmunotherapy
  • 批准号:
    10231261
  • 项目类别:
  • 资助金额:
    $19.41万
  • 财政年份:
    2020
  • 负责人:
    KRISTOFFER Carl VALERIE
  • 依托单位:
Novel, orally available ATM inhibitor for glioma conformal radiosensitization
  • 批准号:
    9184543
  • 项目类别:
  • 资助金额:
    $16.58万
  • 财政年份:
    2015
  • 负责人:
    KRISTOFFER Carl VALERIE
  • 依托单位:
Targeting invasion and DNA DSB repair in glioma with a multi-pronged approach.
  • 批准号:
    8206662
  • 项目类别:
  • 资助金额:
    $19.51万
  • 财政年份:
    2010
  • 负责人:
    KRISTOFFER Carl VALERIE
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: